PDGF receptors in tumor biology: Prognostic and predictive potential

Future Oncology

Volumn 10, Issue 9, 2014, Pages 1695-1708

  Paulsson, Janna ^a   Ehnman, Monika ^a   Östman, Arne ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

fibroblast; metastasis; PDGF; PDGF receptor; pericyte; prognostic; tumor stroma; tumorigenesis

Indexed keywords

BIOLOGICAL MARKER; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR; TUMOR MARKER;

BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; COLON CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIGESTIVE SYSTEM CANCER; HUMAN; MESENCHYME CELL; PERICYTE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANIMAL; METABOLISM; METASTASIS; NEOPLASM; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; VASCULARIZATION;

ANIMALS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; PERICYTES; PLATELET-DERIVED GROWTH FACTOR; PROGNOSIS; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84906536498     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.83     Document Type: Review

References (115)

1. Ehnman M, Ostman A. Therapeutic targeting of platelet-derived growth factor receptors in solid tumors. Expert Opin. Investig. Drugs 23(2), 211-226 (2013
2. Cao Y. Multifarious functions of PDGFs and PDGFRs in tumor growth and metastasis. Trends Mol. Med. 19(8), 460-473 (2013
3. Heldin CH. Targeting the PDGF signaling pathway in tumor treatment. Cell Commun. Signal. 11, 97 (2013
4. Rand V, Huang J, Stockwell T et al. Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc. Natl Acad. Sci. USA 102(40), 14344-14349 (2005
5. Verhaak RG, Hoadley KA, Purdom E et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1), 98-110 (2010
6. Corless CL, Schroeder A, Griffith D et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J. Clin. Oncol. 23(23), 5357-5364 (2005
7. Heinrich MC, Corless CL, Demetri GD et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21(23), 4342-4349 (2003
8. Shimizu A, O'brien KP, Sjoblom T et al. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res. 59(15), 3719-3723 (1999
9. Simon MP, Pedeutour F, Sirvent N et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat. Genet. 15(1), 95-98 (1997
10. Henriksen R, Funa K, Wilander E, Backstrom T, Ridderheim M, Oberg K. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res. 53(19), 4550-4554 (1993
11. Patel SH, Kneuertz PJ, Delgado M et al. Clinically relevant biomarkers to select patients for targeted inhibitor therapy after resection of hepatocellular carcinoma. Ann. Surg. Oncol. 18(12), 3384-3390 (2011
12. Puget S, Philippe C, Bax DA et al. Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas. PLoS ONE 7(2), e30313 (2012
13. Paugh BS, Zhu X, Qu C et al. Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas. Cancer Res. 73(20), 6219-6229 (2013
14. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77(2), 307-316 (1994
15. Cools J, Deangelo DJ, Gotlib J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348(13), 1201-1214 (2003
16. Cross NC, Reiter A. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Acta Haematol. 119(4), 199-206 (2008
17. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490(7418), 61-70 (2012
18. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489(7417), 519-525 (2012
19. Nazarian R, Shi H, Wang Q et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468(7326), 973-977 (2010
20. Duncan JS, Whittle MC, Nakamura K et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149(2), 307-321 (2012
21. Hermanson M, Funa K, Hartman M et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res. 52(11), 3213-3219 (1992
22. Nazarenko I, Hede SM, He X et al. PDGF and PDGF receptors in glioma. Ups J. Med. Sci. 117(2), 99-112 (2012
23. Joensuu H, Puputti M, Sihto H, Tynninen O, Nupponen NN. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme. J. Pathol. 207(2), 224-231 (2005
24. Jansen MH, Van Vuurden DG, Vandertop WP, Kaspers GJ. Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology. Cancer Treat. Rev. 38(1), 27-35 (2012
25. Paugh BS, Qu C, Jones C et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J. Clin. Oncol. 28(18), 3061-3068 (2010
26. Sjoblom T, Shimizu A, O'brien KP et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res. 61(15), 5778-5783 (2001
27. Malhotra B, Schuetze SM. Dermatofibrosarcoma protruberans treatment with platelet-derived growth factor receptor inhibitor: a review of clinical trial results. Curr. Opin. Oncol. 24(4), 419-424 (2012
28. Dewaele B, Wasag B, Cools J et al. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin. Cancer Res. 14(18), 5749-5758 (2008
29. Phase II Study of Crenolanib (CP-868,596), for the Treatment of Patients With Advanced Gastrointestinal Stromal Tumors With the D842-related Mutations and Deletions in the PDGFRA Gene. www.clinicaltrials.gov/ct2/show/NCT01243346
30. ClinicalTrials.gov www.clinicaltrials.gov/ct2/results?term= dasatinib+AND+GIST&Search=Search
31. Zwerner JP, May WA. PDGF-C is an EWS/FLI induced transforming growth factor in Ewing family tumors. Oncogene 20(5), 626-633 (2001
32. Missiaglia E, Williamson D, Chisholm J et al. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J. Clin. Oncol. 30(14), 1670-1677 (2012
33. Taniguchi E, Nishijo K, Mccleish AT et al. PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene 27(51), 6550-6560 (2008
34. Zwerner JP, May WA. Dominant negative PDGF-C inhibits growth of Ewing family tumor cell lines. Oncogene 21(24), 3847-3854 (2002
35. Uren A, Merchant MS, Sun CJ et al. Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells. Oncogene 22(15), 2334-2342 (2003
36. Reddy K, Zhou Z, Jia SF et al. Stromal cell-derived factor-1 stimulates vasculogenesis and enhances Ewing's sarcoma tumor growth in the absence of vascular endothelial growth factor. Int. J. Cancer 123(4), 831-837 (2008
37. Armulik A, Genove G, Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev. Cell 21(2), 193-215 (2011
38. Sundberg C, Ljungstrom M, Lindmark G, Gerdin B, Rubin K. Microvascular pericytes express platelet-derived growth factor-beta receptors in human healing wounds and colorectal adenocarcinoma. Am. J. Pathol. 143(5), 1377-1388 (1993
39. Abramsson A, Lindblom P, Betsholtz C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J. Clin. Invest. 112(8), 1142-1151 (2003
40. Furuhashi M, Sjoblom T, Abramsson A et al. Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. Cancer Res. 64(8), 2725-2733 (2004
41. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111(9), 1287-1295 (2003
42. Mccarty MF, Somcio RJ, Stoeltzing O et al. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. J. Clin. Invest. 117(8), 2114-2122 (2007
43. Nisancioglu MH, Betsholtz C, Genove G. The absence of pericytes does not increase the sensitivity of tumor vasculature to vascular endothelial growth factor-A blockade. Cancer Res. 70(12), 5109-5115 (2010
44. Hosaka K, Yang Y, Seki T et al. Tumour PDGF-BB expression levels determine dual effects of anti-PDGF drugs on vascular remodelling and metastasis. Nat. Commun. 4, 2129 (2013
45. Apte SM, Fan D, Killion JJ, Fidler IJ. Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma. Clin. Cancer Res. 10(3), 897-908 (2004
46. Hwang RF, Yokoi K, Bucana CD et al. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin. Cancer Res. 9(17), 6534-6544 (2003
47. Lev DC, Kim SJ, Onn A et al. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice. Clin. Cancer Res. 11(1), 306-314 (2005
48. Uehara H, Kim SJ, Karashima T et al. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J. Natl Cancer Inst. 95(6), 458-470 (2003
49. Cao R, Bjorndahl MA, Religa P et al. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 6(4), 333-345 (2004
50. Greenberg JI, Shields DJ, Barillas SG et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 456(7223), 809-813 (2008
51. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 22(10), 1276-1312 (2008
52. Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 316(8), 1324-1331 (2010
53. Skobe M, Fusenig NE. Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. Proc. Natl Acad. Sci. USA 95(3), 1050-1055 (1998
54. Anderberg C, Li H, Fredriksson L et al. Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts. Cancer Res. 69(1), 369-378 (2009
55. Forsberg K, Valyi-Nagy I, Heldin CH, Herlyn M, Westermark B. Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proc. Natl Acad. Sci. USA 90(2), 393-397 (1993
56. Pietras K, Pahler J, Bergers G, Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med. 5(1), e19 (2008
57. Kitadai Y, Sasaki T, Kuwai T, Nakamura T, Bucana CD, Fidler IJ. Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma. Am. J. Pathol. 169(6), 2054-2065 (2006
58. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev. 46(1-3), 149-168 (2001
59. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure-an obstacle in cancer therapy. Nat. Rev. Cancer 4(10), 806-813 (2004
60. Baranowska-Kortylewicz J, Abe M, Pietras K et al. Effect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy. Cancer Res. 65(17), 7824-7831 (2005
61. Pietras K, Ostman A, Sjoquist M et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 61(7), 2929-2934 (2001
62. Pietras K, Rubin K, Sjoblom T et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 62(19), 5476-5484 (2002
63. Pietras K, Stumm M, Hubert M et al. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin. Cancer Res. 9(10 Pt 1), 3779-3787 (2003
64. Gotzmann J, Fischer AN, Zojer M et al. A crucial function of PDGF in TGF-beta-mediated cancer progression of hepatocytes. Oncogene 25(22), 3170-3185 (2006
65. Jechlinger M, Sommer A, Moriggl R et al. Autocrine PDGFR signaling promotes mammary cancer metastasis. J. Clin. Invest. 116(6), 1561-1570 (2006
66. Tiwari N, Tiwari VK, Waldmeier L et al. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming. Cancer Cell 23(6), 768-783 (2013
67. Najy AJ, Jung YS, Won JJ et al. Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction. Prostate 72(12), 1328-1338 (2012
68. Xian X, Hakansson J, Stahlberg A et al. Pericytes limit tumor cell metastasis. J. Clin. Invest. 116(3), 642-651 (2006
69. Cooke VG, Lebleu VS, Keskin D et al. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 21(1), 66-81 (2012
70. Pena C, Cespedes MV, Lindh MB et al. STC1 expression by cancer-associated fibroblasts drives metastasis of colorectal cancer. Cancer Res. 73(4), 1287-1297 (2013
71. Shinagawa K, Kitadai Y, Tanaka M et al. Stroma-directed imatinib therapy impairs the tumor-promoting effect of bone marrow-derived mesenchymal stem cells in an orthotopic transplantation model of colon cancer. Int. J. Cancer 132(4), 813-823 (2013
72. Jarvius M, Paulsson J, Weibrecht I et al. In situ detection of phosphorylated platelet-derived growth factor receptor beta using a generalized proximity ligation method. Mol. Cell Proteomics 6(9), 1500-1509 (2007
73. Frings O, Augsten M, Tobin NP et al. Prognostic significance in breast cancer of a gene signature capturing stromal PDGF signaling. Am. J. Pathol. 182(6), 2037-2047 (2013
74. Varela M, Ranuncolo SM, Morand A et al. EGF-R and PDGF-R, but not bcl-2, overexpression predict overall survival in patients with low-grade astrocytomas. J. Surg. Oncol. 86(1), 34-40 (2004
75. Ribom D, Andrae J, Frielingsdorf M, Hartman M, Nister M, Smits A. Prognostic value of platelet derived growth factor alpha receptor expression in grade 2 astrocytomas and oligoastrocytomas. J. Neurol. Neurosurg. Psychiatry 72(6), 782-787 (2002
76. Martinho O, Longatto-Filho A, Lambros MB et al. Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas. Br. J. Cancer 101(6), 973-982 (2009
77. Paulsson J, Lindh MB, Jarvius M et al. Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma. Int. J. Cancer 128(8), 1981-1988 (2011
78. Moreno L, Popov S, Jury A, Al Sarraj S, Jones C, Zacharoulis S. Role of platelet derived growth factor receptor (PDGFR) over-expression and angiogenesis in ependymoma. J. Neurooncol. 111(2), 169-176 (2013
79. Shimada A, Hirato J, Kuroiwa M et al. Expression of KIT and PDGFR is associated with a good prognosis in neuroblastoma. Pediatr. Blood Cancer 50(2), 213-217 (2008
80. Ghanem M, Nijman R, Safan M, Van Der Kwast T, Vansteenbrugge G. Expression and prognostic value of platelet-derived growth factor-AA and its receptor alpha in nephroblastoma. BJU Int. 106(9), 1389-1393 (2010
81. Hagglof C, Hammarsten P, Josefsson A et al. Stromal PDGFRbeta expression in prostate tumors and non-malignant prostate tissue predicts prostate cancer survival. PLoS ONE 5(5), e10747 (2010
82. Ariad S, Seymour L, Bezwoda WR. Platelet-derived growth factor (PDGF) in plasma of breast cancer patients: correlation with stage and rate of progression. Breast Cancer Res. Treat 20(1), 11-17 (1991
83. Seymour L, Bezwoda WR. Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancer. Breast Cancer Res. Treat 32(2), 229-233 (1994
84. Carvalho I, Milanezi F, Martins A, Reis RM, Schmitt F. Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res. 7(5), R788-795 (2005
85. Paulsson J, Sjoblom T, Micke P et al. Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am. J. Pathol. 175(1), 334-341 (2009
86. Donnem T, Al-Saad S, Al-Shibli K, Andersen S, Busund LT, Bremnes RM. Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells. J. Thorac. Oncol. 3(9), 963-970 (2008
87. Donnem T, Al-Saad S, Al-Shibli K, Busund LT, Bremnes RM. Co-expression of PDGF-B and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small-cell lung cancer. Ann. Oncol. 21(2), 223-231 (2010
88. Donnem T, Andersen S, Al-Saad S, Al-Shibli K, Busund LT, Bremnes RM. Prognostic impact of angiogenic markers in non-small-cell lung cancer is related to tumor size. Clin. Lung Cancer 12(2), 106-115 (2011
89. Rahbari NN, Schmidt T, Falk CS et al. Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer. BMC Cancer 11, 286 (2011
90. Yuzawa S, Kano MR, Einama T, Nishihara H. PDGFRbeta expression in tumor stroma of pancreatic adenocarcinoma as a reliable prognostic marker. Med. Oncol. 29(4), 2824-2830 (2012
91. Knosel T, Chen Y, Altendorf-Hofmann A et al. High KIT and PDGFRA are associated with shorter patients survival in gastroenteropancreatic neuroendocrine tumors, but mutations are a rare event. J. Cancer Res. Clin. Oncol. 138(3), 397-403 (2012
92. Kodama M, Kitadai Y, Sumida T et al. Expression of platelet-derived growth factor (PDGF)-B and PDGF-receptor beta is associated with lymphatic metastasis in human gastric carcinoma. Cancer Sci. 101(9), 1984-1989 (2010
93. Guo Y, Yin J, Zha L, Wang Z. Clinicopathological significance of platelet-derived growth factor B, platelet-derived growth factor receptor-beta, and E-cadherin expression in gastric carcinoma. Contemp Oncol (Pozn) 17(2), 150-155 (2013
94. Suzuki S, Dobashi Y, Hatakeyama Y et al. Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-beta phosphorylation, and microvessel density in gastric cancer. BMC Cancer 10, 659 (2010
95. Katano M, Nakamura M, Fujimoto K, Miyazaki K, Morisaki T. Prognostic value of platelet-derived growth factor-A (PDGF-A) in gastric carcinoma. Ann. Surg. 227(3), 365-371 (1998
96. Matsumoto S, Yamada Y, Narikiyo M et al. Prognostic significance of platelet-derived growth factor-BB expression in human esophageal squamous cell carcinomas. Anticancer Res. 27(4B), 2409-2414 (2007
97. Nakamura Y, Tanaka F, Yoshikawa Y et al. PDGF-BB is a novel prognostic factor in colorectal cancer. Ann. Surg. Oncol. 15(8), 2129-2136 (2008
98. Boonjaraspinyo S, Boonmars T, Wu Z et al. Platelet-derived growth factor may be a potential diagnostic and prognostic marker for cholangiocarcinoma. Tumour Biol. 33(5), 1785-1802 (2012
99. Lassus H, Sihto H, Leminen A et al. Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma. Br. J. Cancer 91(12), 2048-2055 (2004
100. Dabrow MB, Francesco MR, Mcbrearty FX, Caradonna S. The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium. Gynecol. Oncol. 71(1), 29-37 (1998
101. Sulzbacher I, Birner P, Traxler M, Marberger M, Haitel A. Expression of platelet-derived growth factor-alpha alpha receptor is associated with tumor progression in clear cell renal cell carcinoma. Am. J. Clin. Pathol. 120(1), 107-112 (2003
102. Kusuda Y, Miyake H, Behnsawy HM, Fukuhara T, Inoue TA, Fujisawa M. Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens. Urol. Oncol. 31(1), 42-50 (2013
103. Chu JS, Ge FJ, Zhang B et al. Expression and prognostic value of VEGFR-2, PDGFR-beta, and c-Met in advanced hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 32, 16 (2013
104. Nupponen NN, Paulsson J, Jeibmann A et al. Platelet-derived growth factor receptor expression and amplification in choroid plexus carcinomas. Mod. Pathol. 21(3), 265-270 (2008
105. Koos B, Paulsson J, Jarvius M et al. Platelet-derived growth factor receptor expression and activation in choroid plexus tumors. Am. J. Pathol. 175(4), 1631-1637 (2009
106. Blandford MC, Barr FG, Lynch JC, Randall RL, Qualman SJ, Keller C. Rhabdomyosarcomas utilize developmental, myogenic growth factors for disease advantage: a report from the Children's Oncology Group. Pediatr. Blood Cancer 46(3), 329-338 (2006
107. Schaefer KL, Eisenacher M, Braun Y et al. Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. Eur. J. Cancer 44(5), 699-709 (2008
108. Ehnman M, Missiaglia E, Folestad E et al. Distinct effects of ligand-induced PDGFRalpha and PDGFRbeta signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments. Cancer Res. 73(7), 2139-2149 (2013
109. Dornbusch J, Zacharis A, Meinhardt M et al. Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma. PLoS ONE 8(9), e76386 (2013
110. Bradic Lindh M, Mezheyeuski A, Glimelius B et al. Tumor perivascular PDGFBR as an independent prognostic factor in metastatic colorectal cancer. Presented at: 2013 ASCO Annual Meeting, Chigago, IL, USA, 31 May-4 June 2013
111. Ostman A. The tumor microenvironment controls drug sensitivity. Nat. Med. 18(9), 1332-1334 (2012
112. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J. Clin. Oncol. 23(5), 939-952 (2005
113. Lindstrom LS, Karlsson E, Wilking UM et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J. Clin. Oncol. 30(21), 2601-2608 (2012
114. Lindborg M, Cortez E, Hoiden-Guthenberg I et al. Engineered high-affinity affibody molecules targeting platelet-derived growth factor receptor beta in vivo. J. Mol. Biol. 407(2), 298-315 (2011
115. Feldwisch J, Tolmachev V, Lendel C et al. Design of an optimized scaffold for affibody molecules. J. Mol. Biol. 398(2), 232-247 (2010).